Avinger Stock Forecast, Price & News

Avinger (NASDAQ:AVGR) Frequently Asked Questions

Is Avinger a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Avinger stock.
View analyst ratings for Avinger or view top-rated stocks.

How has Avinger's stock price been impacted by COVID-19 (Coronavirus)?

Avinger's stock was trading at $0.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, AVGR stock has decreased by 25.3% and is now trading at $0.3210.
View which stocks have been most impacted by COVID-19.

Are investors shorting Avinger?

Avinger saw a increase in short interest during the month of December. As of December 31st, there was short interest totaling 789,600 shares, an increase of 26.2% from the December 15th total of 625,600 shares. Based on an average daily volume of 1,800,000 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.8% of the shares of the company are sold short.
View Avinger's Short Interest.

When is Avinger's next earnings date?

Avinger is scheduled to release its next quarterly earnings announcement on Thursday, March 10th 2022.
View our earnings forecast for Avinger.

How were Avinger's earnings last quarter?

Avinger, Inc. (NASDAQ:AVGR) issued its quarterly earnings results on Thursday, November, 11th. The medical device company reported ($0.06) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.07) by $0.01. The medical device company had revenue of $2.37 million for the quarter, compared to the consensus estimate of $2.52 million. Avinger had a negative trailing twelve-month return on equity of 109.27% and a negative net margin of 162.98%. During the same quarter in the previous year, the company earned ($0.08) EPS.
View Avinger's earnings history.

When did Avinger's stock split? How did Avinger's stock split work?

Avinger's stock reverse split before market open on Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split.

What price target have analysts set for AVGR?

2 equities research analysts have issued 1-year price objectives for Avinger's stock. Their forecasts range from $2.00 to $2.50. On average, they anticipate Avinger's stock price to reach $2.25 in the next year. This suggests a possible upside of 600.9% from the stock's current price.
View analysts' price targets for Avinger or view top-rated stocks among Wall Street analysts.

Who are Avinger's key executives?

Avinger's management team includes the following people:

• Jeffrey M. Soinski, President, Chief Executive Officer & Director
• Mark B. Weinswig, Chief Financial Officer
• Himanshu N. Patel, Chief Technology Officer
• Jaafer Golzar, Chief Medical Officer
• Philip R. Preuss, Vice President-Marketing & Business Operations

Who are some of Avinger's key competitors?

Some companies that are related to Avinger include BrainsWay (BWAY), Repro-Med Systems (REPR), Nemaura Medical (NMRD), Neuronetics (STIM), PolyPid (PYPD), Venus Concept (VERO), Pro-Dex (PDEX), AIT Therapeutics (AITB), SANUWAVE Health (SNWV), Acutus Medical (AFIB), T2 Biosystems (TTOO), Titan Medical (TMDI), Assure (IONM), LENSAR (LNSR) and Integrity Applications (IGAP).
View all of AVGR's competitors.

What other stocks do shareholders of Avinger own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Bionano Genomics (BNGO), Novan (NOVN), Titan Pharmaceuticals (TTNP), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), OrganiGram (OGI), Onconova Therapeutics (ONTX), ADMA Biologics (ADMA), Aeterna Zentaris (AEZS) and Actinium Pharmaceuticals (ATNM).

When did Avinger IPO?

(AVGR) raised $60 million in an initial public offering on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers.

What is Avinger's stock symbol?

Avinger trades on the NASDAQ under the ticker symbol "AVGR."

How do I buy shares of Avinger?

Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Avinger's stock price today?

One share of AVGR stock can currently be purchased for approximately $0.32.

How much money does Avinger make?

Avinger has a market capitalization of $30.68 million and generates $8.76 million in revenue each year. The medical device company earns $-19.01 million in net income (profit) each year or ($0.24) on an earnings per share basis.

How many employees does Avinger have?

Avinger employs 72 workers across the globe.

What is Avinger's official website?

The official website for Avinger is www.avinger.com.

Where are Avinger's headquarters?

Avinger is headquartered at 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063.

How can I contact Avinger?

Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at (650) 241-7900, via email at [email protected], or via fax at 800-229-2696.